HERTHENA-Breast04: what clinicians are saying
patritumab deruxtecan in hormone receptor-positive, HER2-negative unresectable locally advanced or metastatic breast cancer · NCT07060807 ↗ · Phase 3 · Merck Sharp & Dohme LLC
A medical oncologist viewed HERTHENA-Breast04 as a test of an ICARUS-B01 signal they considered comparable to T-DXd; that comparison rested on single-arm evidence. Commentary on the trial itself is limited. In the broader post-CDK4/6 discussion, a hematology-oncology physician would defer capecitabine or sacituzumab in a case they did not consider endocrine resistant. The sources reviewed for this edition contain no publication reporting the trial’s outcomes.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 27 verified statements
This edition $750, with MCP access for your AI agent. Get this report
6 findings, and what sits behind each
01. Entry: a speaker sees possible access & contribution, no assured survival
No named clinician · accounts and unnamed speakers · 5 statements in 1 source, a podcast or video · 1 passage
Limitations recorded: 3.
Draws on: Primary endpoint: Progression Free Survival (PFS), Primary endpoint: Overall Survival (OS), Population and setting, Safety and tolerability, Secondary endpoints, The comparison.
Beyond the trial population
02. HERTHENA-Breast04: why a clinician sees it as confirmatory after ICARUS-B01
1 of the report's 4 cited clinicians · 1 statement from 1 speaker in 1 source · 2 passages
Limitations recorded: 2.
03. Endocrine-sensitive case: a clinician defers chemo but excludes Trastuzumab deruxtecan
1 of the report's 4 cited clinicians · 7 statements from 1 speaker in 3 sources, 1 of them a podcast or video · 9 passages
Limitations recorded: 3.
04. 1L progression: what speakers say
1 of the report's 4 cited clinicians · 3 statements from 1 speaker in 2 sources · 3 passages
Limitations recorded: 2.
05. Second line: a clinician sees options, no known order; one queries prognosis
3 of the report's 4 cited clinicians · 8 statements from 3 speakers in 2 sources · 8 passages
Limitations recorded: 3.
06. ICARUS-BREAST01: what a speaker highlights in the translational work
No named clinician · accounts and unnamed speakers · 2 statements from 1 speaker in 1 source · 2 passages
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
No named clinician · accounts and unnamed speakers
Entry: a speaker sees possible access & contribution, no assured survival
5 statements in 1 source, a podcast or video
No named speaker is counted in this finding: its title's view comes from speakers the source does not name
- 5
- statements
- 1
- passage
- 1
- source
- 0
- speakers
What the statements areViews 1Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 4Statement-to-passage links (a passage can back several statements)Supporting a statement 5Giving context 5Recorded with the findingLimitations: 3
1 podcast or video
Draws on: Primary endpoint: Progression Free Survival (PFS), Primary endpoint: Overall Survival (OS), Population and setting, Safety and tolerability, Secondary endpoints, The comparison.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
5 of the 6 findings and 20 of the 27 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (8)
ADC, antibody–drug conjugate; HCP, healthcare professional; HER2, human epidermal growth factor receptor 2; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan.
The full HERTHENA-Breast04 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 28commentary sources screened
- 5sources cited by verified statements
- 5named in screened sources
- 5speakers cited in the report
- 5cited speakers with a verified identity
4 cited clinicians, speakers with a confirmed clinical role, of them 4 physicians. By role and specialty:
- 2 physician, Medical oncology
- 1 physician, specialty not confirmed
- 1 physician, Hematology and oncology
Also in the sources: 1 organizational or shared account, not counted as people.
- 27verified statements, each linked to its source
- 13of them from speakers with a confirmed clinical role
- 6findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 27 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 4 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 5 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
11 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression Free Survival (PFS) | 2 | 1 |
| Primary endpoint: Overall Survival (OS) | 2 | 1 |
| Secondary endpoints | 1 | 1 |
| Population and setting | 2 | 1 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 2 | 2 |
| Safety and tolerability | 2 | 1 |
| Design and conductno commentary found | 0 | 0 |
| Endocrine-treatment boundary and the case-specific IHC 0 ADC judgment | 6 | 2 |
| Molecular work-up at progression | 3 | 2 |
| Second-line options, sequencing and the prognosis question after early progression | 7 | 2 |
| Earlier HER3-DXd evidence informing phase 3 expectations | 3 | 2 |
| Participation, possible access and patient communication | 2 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
27 verified statements from 5 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 5 statements · 19% | ||||
| YouTube | 5 | 1 | 1 | |
| Posts · 22 statements · 81% | ||||
| X threads | 14 | 3 | 20 | |
| Bluesky threads | 8 | 1 | 7 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 17 / quarter
- Screened window
- Aug 27, 2025 → Oct 23, 2026
- Cited window
- Sep 4, 2025 → Feb 11, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).
- Registry
- NCT07060807
- Study IDs
- 1022-016 · U1111-1317-5490 (UTN) · 2025-520582-51-00 (EU CT) · jRCT2031250297 (Japan Registry of Clinical Trial (jRCT))
- Sponsor
- Merck Sharp & Dohme LLC
- Collaborators
- Daiichi Sankyo
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 1,000 estimated
- Registered
- 2025-07-11
- Start
- 2025-07-21 actual
- Primary completion
- 2033-07-14 estimated
- Primary endpoints
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Interventions
- 7 registered
More on: Breast cancer, patritumab deruxtecan
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 4 passages in 3 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 70 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 35 sources about other trials or topics are not included.
- These source-specific statements do not establish the prevalence of a view among HCPs or a clinical consensus.
Show all 10 known gaps +Fewer −
- Some passages in the case discussions and patient-information video were not fully assessed, and discussion without trial names or identifiers may be missing.
- No full protocol or publication reporting HERTHENA-Breast04 outcomes was included in the sources reviewed for this edition; earlier phase 2 evidence and planned assessments must not be read as phase 3 findings.
- Drug-label information was incomplete, including no exact label identified for Patritumab deruxtecan or Nab-paclitaxel. The report does not independently resolve labeled use or eligibility.
- Parallel X and Bluesky content and reposts should not be counted as independent clinical agreement.
- The individual author behind a speaker is not established. The patient-information video's statements are not attributable to a proven named clinician.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. HERTHENA-Breast04 (NCT07060807): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/herthena-breast04-nct07060807
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "HERTHENA-Breast04" (NCT07060807), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "herthena-breast04-nct07060807". If you cannot make requests, read https://www.erudio.com/reports/herthena-breast04-nct07060807.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07060807", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07060807 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/herthena-breast04-nct07060807.json
curl https://www.erudio.com/reports/herthena-breast04-nct07060807.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "herthena-breast04-nct07060807" })release 637ebb1e5136d9b2756d6ceca3c5ed86c880f1c16c7f8ad82b276d3da55bd06e
Questions
How much does the HERTHENA-Breast04 report cost?
One edition costs $750 (Focused · 27 verified statements · 13 from 4 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the HERTHENA-Breast04 report cover?
27 statements from 5 sources (1 video, 4 posts), 13 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the HERTHENA-Breast04 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "herthena-breast04-nct07060807" }) previews it and create_order({ "report": "herthena-breast04-nct07060807", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the HERTHENA-Breast04 report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.